# A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

> **NCT05108623** · PHASE1 · COMPLETED · sponsor: **MiNK Therapeutics** · enrollment: 34 (actual)

## Conditions studied

- Tumor, Solid

## Interventions

- **DRUG:** agenT-797
- **DRUG:** Approved ICIs

## Key facts

- **NCT ID:** NCT05108623
- **Lead sponsor:** MiNK Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-28
- **Primary completion:** 2024-01-02
- **Final completion:** 2024-01-02
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05108623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05108623, "A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05108623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*